{"schema":"sb.node.v1","id":"sb:e/38503bf4435c9372bed40d46","kind":"entity","label":{"text":"astrazeneca","locale":"en"},"identity":{"anchor":"label:en:astrazeneca","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-09T23:33:39.923351+00:00","snapshot":"deploy f22bd66b225b3901cd1996e08079b5893bdf41be"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":143,"separatePublishers":49,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":1,"named":11,"of":11,"basis":"receipts the entity graph keeps whose own headline names the subject, over all receipts it keeps for the subject (the door's measurement; the graph carries none of its own). Only the former are served"}},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-05-05","to":"2026-10-09","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.301: about 70% of mentions carry no typed assertion"]}},"dimensions":{"domains":["fda_decisions","biotech_pharma","auto"],"activeDays":38,"assertions":{"regulatory-approval":21,"meeting-visit":8,"funding-round":3,"acquisition":3,"launch-release":2,"military-action":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":11,"byKind":{"observation":11},"withheld":{"state":"withheld","count":1,"reason":"1 receipt withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/019eccada7401dda1ae1cc49","kind":"observation","label":"STAT News · 2026-10-07 · STAT+: Pharmalittle: We’re reading about U.S.-funded psychedelic trials, an AstraZeneca R&D center, and more","url":"https://www.statnews.com/pharmalot/2026/10/06/us-funded-psychedelic-trials-astrazeneca-research-center/?utm_campaign=rss"},{"id":"sb:o/e05f414bf6650f1f25f41cea","kind":"observation","label":"STAT News · 2026-10-07 · STAT+: AstraZeneca opens new Boston site","url":"https://www.statnews.com/2026/10/06/biotech-news-astrazeneca-opens-new-boston-site/?utm_campaign=rss"},{"id":"sb:o/bef15b240e1065ad0fc12ad2","kind":"observation","label":"Endpoints News · 2026-10-03 · Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone","url":"https://endpoints.news/summit-partners-with-astrazeneca-and-daiichi-eccogene-earns-50m-milestone/"},{"id":"sb:o/eb86097d896d3fbaef88184c","kind":"observation","label":"AllSci News · 2026-10-02 · AstraZeneca, Daiichi team with Summit to pair Datroway with ivonescimab in Phase III TNBC push","url":"https://allsci.com/news/biotech/datroway-ivonescimab-astrazeneca-and-daiichi/"},{"id":"sb:o/53716d1e845ae3021b50717e","kind":"observation","label":"STAT News · 2026-09-30 · STAT+: AstraZeneca invests $2 billion in Summit Therapeutics","url":"https://www.statnews.com/2026/09/29/biotech-news-astrazeneca-invests-2-billion-in-summit-therapeautics/?utm_campaign=rss"},{"id":"sb:o/afefb7b3bc5e4f361a95f937","kind":"observation","label":"Fierce Pharma · 2026-09-30 · Hansoh’s Tagrisso rival loses EU approval after AstraZeneca legal challenge","url":"https://www.fiercepharma.com/pharma/hansoh-tagrisso-rival-loses-eu-approval-after-astrazeneca-legal-challenge"},{"id":"sb:o/8b99a1ff1e36270fb40ef63b","kind":"observation","label":"AllSci News · 2026-09-30 · AstraZeneca wins Priority Review for Imfinzi-EV regimen in bladder cancer","url":"https://allsci.com/news/biotech/imfinzi-enfortumab-bladder-cancer-fda-grants/"},{"id":"sb:o/f4315f164534eb52402506b7","kind":"observation","label":"AllSci News · 2026-09-30 · AstraZeneca seeks FDA approval for HutchMed's Orpathys plus Tagrisso in MET-driven lung cancer","url":"https://allsci.com/news/biotech/savolitinib-fda-approval-astrazeneca-seeks-for/"},{"id":"sb:o/36d42651c1379e751c186f97","kind":"observation","label":"AllSci News · 2026-09-30 · AstraZeneca invests USD 2b in Summit to advance ivonescimab-ADC combination trials","url":"https://allsci.com/news/biotech/astrazeneca-summit-investment-ivonescimab/"},{"id":"sb:o/272d6e15e41da181e0df9835","kind":"observation","label":"BioPharma Dive · 2026-09-30 · AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push","url":"https://www.biopharmadive.com/news/summit-astrazeneca-ivonescimab-deal-pd1-vegf/752865/"}],"cursor":"c1.eyJpZCI6InNiOmUvMzg1MDNiZjQ0MzVjOTM3MmJlZDQwZDQ2IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA5VDIzOjMzOjM5LjkyMzM1MSswMDowMCJ9","order":"newest first; we keep the 11 newest receipts for this entity whose own headline names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with fda (48 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/75d77b844d609bd5d201c443"},{"kind":"relation","label":"co-mentioned with novartis (42 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e619c87e8d550acd872566af"},{"kind":"relation","label":"co-mentioned with china (37 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/8ef244956559a5401098ede5"},{"kind":"relation","label":"co-mentioned with roche (34 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/3ca75e698cdbb9f94aed4ab6"},{"kind":"relation","label":"co-mentioned with eli lilly (33 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/ee6825592b1f70dc7e46bfe9"},{"kind":"relation","label":"co-mentioned with merck (33 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/42ee49b3cc5e168f2c141558"},{"kind":"relation","label":"co-mentioned with pfizer (32 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/3af721897a3e1c068922d746"},{"kind":"relation","label":"co-mentioned with ai (29 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/12d334d43f193752ca61c8d8"},{"kind":"relation","label":"co-mentioned with bristol myers squibb (28 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4787682d12297b7a7b4919dd"},{"kind":"relation","label":"co-mentioned with clinical trials (28 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/70fc6389f0e0dfdfc6f0f668"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/38503bf4435c9372bed40d46","mcp":"traverse {\"id\":\"sb:e/38503bf4435c9372bed40d46\"}","page":"/entity/astrazeneca/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/38503bf4435c9372bed40d46\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/38503bf4435c9372bed40d46\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/38503bf4435c9372bed40d46\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/38503bf4435c9372bed40d46\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}